ADVENTRX Pharmaceuticals and Pierre Fabre Medicament have entered into a multi-year agreement under which Pierre Fabre will produce the active ingredient in ANX-188 (purified poloxamer 188) for use in clinical trials.   “We are delighted that the two companies have signed this multi-year agreement,” said Frederic Duchesne, president of the Pharmaceuticals Division of Pierre Fabre. “Such a partnership is very exciting for the whole Pierre Fabre team. We are convinced of the high...